These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2962503)

  • 1. Characterization of renal injury initiated by immunization of rats with heparan sulfate.
    Abrass CK; Cohen AH
    Am J Pathol; 1988 Jan; 130(1):103-11. PubMed ID: 2962503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening.
    Miettinen A; Stow JL; Mentone S; Farquhar MG
    J Exp Med; 1986 May; 163(5):1064-84. PubMed ID: 2939168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis.
    Kashihara N; Makino H; Szekanecz Z; Waltenbaugh CR; Kanwar YS
    Lab Invest; 1992 Dec; 67(6):752-60. PubMed ID: 1460866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephritogenicity of antibodies to proteoglycans of the glomerular basement membrane--I.
    Makino H; Gibbons JT; Reddy MK; Kanwar YS
    J Clin Invest; 1986 Jan; 77(1):142-56. PubMed ID: 2935558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basement membrane heparan sulfate proteoglycans are concentrated in the laminae rarae and in podocytes of the rat renal glomerulus.
    Stow JL; Sawada H; Farquhar MG
    Proc Natl Acad Sci U S A; 1985 May; 82(10):3296-300. PubMed ID: 3159016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephritogenicity of proteoglycans. III. Mechanism of immune deposit formation.
    Makino H; Lelongt B; Kanwar YS
    Kidney Int; 1988 Aug; 34(2):209-19. PubMed ID: 2972860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate.
    van den Born J; van Kraats AA; Bakker MA; Assmann KJ; van den Heuvel LP; Veerkamp JH; Berden JH
    Diabetologia; 1995 Feb; 38(2):161-72. PubMed ID: 7713310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephritogenicity of proteoglycans. II. A model of immune complex nephritis.
    Makino H; Lelongt B; Kanwar YS
    Kidney Int; 1988 Aug; 34(2):195-208. PubMed ID: 2972859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparan sulfate staining of the glomerular basement membrane in relation to circulating anti-DNA and anti-heparan sulfate reactivity: a longitudinal study in NZB/W F1 mice.
    Hylkema MN; van Bruggen MC; van de Lagemaat R; Kramers K; Berden JH; Smeenk RJ
    J Autoimmun; 1996 Feb; 9(1):41-50. PubMed ID: 8845053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of heparan sulfate in the glomerular basement membrane.
    Kanwar YS; Farquhar MG
    Proc Natl Acad Sci U S A; 1979 Mar; 76(3):1303-7. PubMed ID: 155819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of immune complexes with glomerular heparan sulfate-proteoglycans.
    Kanwar YS; Caulin-Glaser T; Gallo GR; Lamm ME
    Kidney Int; 1986 Dec; 30(6):842-51. PubMed ID: 2950267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of heparan sulfate from the glomerular basement membrane blocks protein passage.
    Wijnhoven TJ; Lensen JF; Wismans RG; Lefeber DJ; Rops AL; van der Vlag J; Berden JH; van den Heuvel LP; van Kuppevelt TH
    J Am Soc Nephrol; 2007 Dec; 18(12):3119-27. PubMed ID: 18003778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of a monoclonal antibody against human glomerular heparan sulfate.
    van den Born J; van den Heuvel LP; Bakker MA; Veerkamp JH; Assmann KJ; Berden JH
    Lab Invest; 1991 Sep; 65(3):287-97. PubMed ID: 1890809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered glomerular localization of heparan sulfate proteoglycan in experimental nephritides.
    Uchida M; Shibata N; Katoh M; Shigematsu H
    Acta Pathol Jpn; 1986 Jun; 36(6):827-38. PubMed ID: 2945356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal localization of heparan sulfate proteoglycan by immunohistochemistry.
    Klein DJ; Oegema TR; Eisenstein R; Furcht L; Michael AF; Brown DM
    Am J Pathol; 1983 Jun; 111(3):323-30. PubMed ID: 6222657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of heparan sulfate isolated from drug glomerular basement membranes.
    Linker A; Hovingh P; Kanwar YS; Farquhar MG
    Lab Invest; 1981 Jun; 44(6):560-5. PubMed ID: 6453253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephritogenic potential of sheep antibodies against glomerular basement membrane laminin in the rat.
    Feintzeig ID; Abrahamson DR; Cybulsky AV; Dittmer JE; Salant DJ
    Lab Invest; 1986 May; 54(5):531-42. PubMed ID: 3517487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of systemic lupus erythematosus-like disease in mice by immunization with heparan sulfate.
    Ofosu-Appiah W; Sfeir G; Viti D; Burashnikova E
    Cell Immunol; 1998 Jan; 183(1):22-31. PubMed ID: 9578716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.
    Reynolds J; Moss J; Duda MA; Smith J; Karkar AM; Macherla V; Shore I; Evans DJ; Woodrow DF; Pusey CD
    J Pathol; 2003 May; 200(1):118-29. PubMed ID: 12692850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the terminal complement pathway in accelerated autologous anti-glomerular basement membrane nephritis.
    Groggel GC; Terreros DA
    Am J Pathol; 1990 Mar; 136(3):533-40. PubMed ID: 2180310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.